Evaluation The Era of ADCs in the Treatment of NSCLC: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Barbara Melosky, MD 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Describe the basics of ADC targeted therapy in the treatment of NSCLC to include MOA, general properties, class related toxicities/side effects etc. 5 4 3 2 1 Appropriately incorporate TROP2, HER3, c-MET and CEACAM5 molecular testing into precision medicine programs for patients with NSCLC to evaluate potential clinical trial eligibility 5 4 3 2 1 Detail the unique properties and clinical trial programs of investigational ADCs targeting TROP2, HER3, c-MET, and CEACAM5 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with NSCLC on a weekly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage NSCLC. Excellent Very Good Good Fair Poor Do you intend to make any changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Based on my participation in this activity, I anticipate I will more often: (select all that apply) Remain up-to-date with the MOAs, general properties, class-related toxicities, and side effects of emerging ADCs for the management of NSCLC Remain apprised of new clinical trial data for investigational TROP2-, HER3-, c-MET-, and CEACAM5-Targeted ADCs that may inform the future landscape of NSCLC Implement TROP2-, HER3-, c-MET-, and CEACAM5 molecular testing in patients with NSCLC to evaluate potential clinical trial eligibility Incorporate newer therapies and sequencing strategies in NSCLC management as they become available for clinical use Implement personalized AE management strategies in NSCLC to ensure treatment efficacy and mitigate treatment risks Other (please specify): Previous
